Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
For the full fiscal 2024, Amgen is expected to deliver an adjusted EPS of $19.57, up 4.9% from $18.65 in fiscal 2023. While in fiscal 2025, its earnings are expected to grow nearly 4% year-over ...
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $328 from $322 and keeps an Equal Weight rating on the ...